The Frost Factor: An M&A Leader's Standout Strategy For Opko Health
With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.
You may also be interested in...
As global market conditions change and companies seek to fill gaps in their service model to payers and patients, are the business interests of originator and generic firms moving closer toward alignment? Surprisingly, the answer may be yes, according to Medicines for Europe director-general Adrian van den Hoven.
Tesaro’s IV formulation of Varubi draws letter keeping with last year’s emerging trend of manufacturing-related CRLs, in this case agency concerns about CMC data related to comparability of drug produced by two different contractors; issue seems unlikely to significantly delay approval of the new version of CINV drug, however.
The life sciences company picks up Transition Therapeutics in an all-stock deal that fleshes out its pipeline.